Skip to content

ONCORADIOMICS

Active Public limited companyfounded 2016active for 10 yearsBoulevard de Patience et Beaujonc 3, 4000 LiègeKBO/BCE: BE 0662.719.440

Lifetime

9 annual accounts with figures on one time axis
peak of €2.4m in 2025
€2.4m▲ 87.8%
lowest -€2.4m in 2022
€284,677▲ €1.4m
peak of €410,086 in 2021
-€3,807▲ €1.0m
€4.3m▼ 10.6%
peak of 28 FTE in 2022
20.2 FTE▼ 14.8%
Board15 names since 2016all names
5 directors and 4 others
Owners3 names in the annual accounts
49.58% and 1 other
Documentsfilings and deeds
03-07-202628 days before the deadline
2025abbreviated format
Gross margin from €1.3m to €2.4mProfit of €284,677, after a lossStaff from 23.7 FTE to 20.2 FTENew independent director 19-05Capital increase 03-01Equity from -€1.0m to -€3,807

Key points

from the 2025 annual accounts

Equity

-€3,807
202020212022202320242025

Debts exceed assets in financial year 2025.

Debts

€4.3m 100% of the balance sheet
Financial debts 65%Suppliers 24%Taxes and wages 3%Other 8%

Of this, €3.4m falls due within a year.

Investments

€1.7m 3.9 times depreciation
20212022202320242025

Green is investment, beige is depreciation.

Staff

13 employees on 31-12-2025
1712202116122022613202310920241132025

In 2025, 1 employee joined and 13 left.

Board

5 joined · 3 left

Board changed. Latest change 22-10-2026 · 7 in office.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 266 companies had the same profile as ONCORADIOMICS has now. Each dot is one company, two years later.

93.6%
were still trading
3.8%
stopped another way
1.1%
went bankrupt
  • Small
  • 10 to 20 years old
  • negative equity
  • a profit of 5% of the balance sheet or more

Another 1.5% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 266 companies, not a prediction for ONCORADIOMICS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Daily manager,
Director
Director, since 28-02-2025
Director,
Director
Auditor
and 3 others
  • 49.58%equity €858,132 (2025) · annual accounts 30-06-2025 of
  • 38.78%equity €212.1m (2025) · annual accounts 30-06-2025 of
Board & ownership

Recent changes

appointed as day-to-day manager acts as permanent representative · Board meeting of 22-09-2026 · Gazette deed
3 directors appointed, 3 resignations, 4 reappointments The capital rose from €270,427.56 to €648,427.56, with 72,411 new shares · The capital rose from €648,427.56 to €748,427.56, with 55,552 new shares · The capital rose from 748.427,56 to 1.598.967,56, with 472,502 new shares · General meeting of 28-08-2026 · Gazette deed
and act as permanent representatives Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0662719440
All 32 events

Comparable companies

same main activity, similar in size and age
Company
ONCORADIOMICS Liège €4.3m €2.4m -0.1% 20.2
BIO-SOURCING Liège €6.6m €1.6m 13.6% 17.3
InnoSer België Diepenbeek €2.1m €3.1m 29.7% 27.4
REJUVENATE BIOMED Diepenbeek €3.5m €3.1m -15.8% 11
TOKU-E EU Ghent €4.2m €1.0m 2.0% 11.8
ORIONIS BIOSCIENCES Ghent €6.9m €5.9m 71.6% 36.3
K5 Therapeutics Leuven €3.6m €2.6m 83.1% 17.8

These companies have the same main activity as ONCORADIOMICS: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €2.1m and €6.9m, founded between 2013 and 2020.

Official details

Source: KBO
Status
Active since 19-09-2016Normal situation
Registered office
48 active companies are registered at this address4 started in the 12 months before. Source: KBO register, as of 18 November 2026.
Activity
Research and development on biotechnologyNACE 72101and 1 other
Joint committee
200Auxiliary committee for white-collar workers · annual accounts 2025
Establishment unit
2.256.770.0294000 Liège, since 19-09-2016
Financial year end
31 December
Peppol
Reachable since 01-12-2025
Company details

Annual accounts 2025

≈ €4.1mestimated
€4.3m▲ 13.3%
Employeeson 31-12-2025
13▼ 48.0%
Filing
Filed on 03-07-2026, 28 days before the end of the filing period
Financials

Insights on ONCORADIOMICS

ONCORADIOMICS files the abbreviated format. That format states no turnover. The gross margin rose from -€267,338 in 2017 to €2.4m in 2025.

In September 2026, three directors stepped down. In October 2026, the Official Gazette published the appointment of as managing director.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about ONCORADIOMICS

What is the company number of ONCORADIOMICS?
The company number of ONCORADIOMICS is 0662.719.440. The VAT number is the same number with BE in front: BE 0662.719.440.
Where is ONCORADIOMICS based?
The registered office is at Boulevard de Patience et Beaujonc 3, 4000 Liège.Company details
What does ONCORADIOMICS do?
According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
What is the legal form of ONCORADIOMICS?
ONCORADIOMICS is a public limited company (NV).
When was ONCORADIOMICS founded?
ONCORADIOMICS was founded on 19-09-2016.
Is ONCORADIOMICS still active?
Yes, ONCORADIOMICS is an active enterprise in the KBO register.
How many employees does ONCORADIOMICS have?
ONCORADIOMICS had an average of 20.2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does ONCORADIOMICS fall under?
In its 2025 annual accounts, ONCORADIOMICS states joint committee 200 (Auxiliary committee for white-collar workers).
What is the turnover of ONCORADIOMICS?
The turnover in financial year 2025 is ≈ €4.1m. This figure is estimated from the gross margin of €2.4m and 1,572 comparable companies of the same size. It probably lies between €2.8m and €6.7m. It is a rough estimate.
Is ONCORADIOMICS profitable?
In financial year 2025, ONCORADIOMICS made a profit of €284,677.
Where can I find the annual accounts of ONCORADIOMICS?
ONCORADIOMICS filed 9 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of ONCORADIOMICS due?
ONCORADIOMICS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.